Sugi Predict

Sugi Predict / Compounds / SCHEMBL12371246

SCHEMBL12371246

SCHEMBL12371246

COCCOCCNC(C)C

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.40
▸ POLB P06746 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ CA2 P00918 2/20 0.37
▸ RECQL P46063 1/20 0.34
▸ HTR1B P28222 2/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ HTR1A P08908 1/20 0.31
▸ ADRB2 P07550 2/20 0.31
▸ ADRB1 P08588 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25129088 1.00 KDM4E (0.40) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL18551591 1.00 KDM4E (0.40) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL19606415 1.00 KDM4E (0.40) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL21839006 1.00 KDM4E (0.40) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL22861638 1.00 KDM4E (0.40) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL19370318 0.91 KDM4E (0.35) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL22837632 0.90 KDM4E (0.44) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL22930120 0.90 KDM4E (0.44) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL18908756 0.90 KDM4E (0.44) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL18908660 0.90 KDM4E (0.44) KDM4EPOLBTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110650785-B Absorbent and process for selective removal of hydrogen sulfide 巴斯夫欧洲公司 2022-05-24 — — CN claimed
EP-3624922-B1 ABSORBENT, PROCESS FOR PRODUCING IT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE USING IT BASF SE (DE) 2021-07-07 — — EP claimed
EP-3624922-A1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE BASF SE (DE) 2020-03-25 — — EP claimed
CN-110650785-A Absorbent and process for selective removal of hydrogen sulfide 巴斯夫欧洲公司 2020-01-03 — — CN claimed
WO-2018210738-A1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE BASF SE (DE) 2018-11-22 — — WO claimed
US-20230165974-A1 COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICALLY ACTIVE AGENTS MEDIMMUNE, LLC 2023-06-01 — — US disclosed
US-20230165974-A1 COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICALLY ACTIVE AGENTS MEDIMMUNE, LLC 2023-06-01 — — US disclosed
WO-2022164997-A1 METHODS FOR THE TREATMENT OF FIBROTIC DISEASE SHY THERAPEUTICS, LLC (US) 2022-08-04 — — WO disclosed
US-20220162173-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-05-26 — — US disclosed
CN-110650785-B Absorbent and process for selective removal of hydrogen sulfide 巴斯夫欧洲公司 2022-05-24 — — CN disclosed
US-11241652-B2 Absorbent and process for selectively removing hydrogen sulfide BASF SE (REITSTÖTTER, KINZEBACH & PARTNER) (DE) 2022-02-08 — — US disclosed
EP-3624922-B1 ABSORBENT, PROCESS FOR PRODUCING IT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE USING IT BASF SE (DE) 2021-07-07 — — EP disclosed
WO-2018210738-A1 ABSORBENT AND PROCESS FOR SELECTIVELY REMOVING HYDROGEN SULFIDE BASF SE (DE) 2018-11-22 — — WO disclosed
US-9951065-B2 Benzimidazole and imadazopyridine carboximidamide compounds GILEAD SCIENCES, INC. (US) 2018-04-24 — — US disclosed
US-20160333009-A1 BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS GILEAD SCIENCES, INC. 2016-11-17 — — US disclosed
US-9050344-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-06-09 — — US disclosed
US-20140221346-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-08-07 — — US disclosed
US-20140221347-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-08-07 — — US disclosed
US-20110202328-A1 System for the determination of selective absorbent molecules through predictive correlations EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2011-08-18 — — US disclosed
US-20110202328-A1 System for the determination of selective absorbent molecules through predictive correlations EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2011-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162173-A1 COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT GABBR1, GABBR2, PMP22 KDM4E 2794/4885POLB 2737/4885TDP1 583/4885
US-20160333009-A1 BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS IDO1, IDO2, INMT KDM4E 366/4885POLB 2086/4885TDP1 578/4885
US-11241652-B2 Absorbent and process for selectively removing hydrogen sulfide C1S, C5, C1R KDM4E 1368/4885POLB 2086/4885TDP1 3509/4885
US-20140221347-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, FURIN KDM4E 4481/4885POLB 1013/4885TDP1 1898/4885
US-20230165974-A1 COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICALLY ACTIVE AGENTS LNPEP, PTMS, PCSK7 KDM4E 256/4885POLB 4057/4885TDP1 2446/4885
US-20140221346-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, G6PD KDM4E 4478/4885POLB 905/4885TDP1 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.